chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 46.0
Sex: F
Vaccine: MMR
Symptoms: Injection site bruising
Clinical narrative: Site: Bruising at Injection Site-Mild, Additional Details: This was  discovered on inventory  count, not  related to this patient specifically because there isn't a way to enter it any other way.  Inventory is 7 vaccine vials  and  4 diluent vials.  This patient did not receive any vaccine this date.
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Pruritus
Clinical narrative: Site: Itching at Injection Site-Severe, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Itch (specify: facial area, extremeties)-Severe, Systemic: Allergic: Rash Generalized-Severe, Systemic: Fever-Severe
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Rash
Clinical narrative: Site: Itching at Injection Site-Severe, Site: Pain at Injection Site-Severe, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Systemic: Allergic: Itch (specify: facial area, extremeties)-Severe, Systemic: Allergic: Rash Generalized-Severe, Systemic: Fever-Severe
Age: 94.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Error: Dose in Series Given Too Early-
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: PAtient noticed an uncomfortable rash/swollen area two days after administration and wished to have it registered.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Additional Details: PAtient noticed an uncomfortable rash/swollen area two days after administration and wished to have it registered.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood catecholamines, Burning sensation, Diarrhoea, Dizziness, Erythema
Clinical narrative: First vaccine- immediate pain down left arm. Within 30 minutes- blurred vision, tingling in lips, hands and feet. Treatment- pharmacist instructed drink pedialyte and rest at home 7 days after first vaccine- dry mouth, tremors, racing heart. Went to ER twice.  Family Dr tried adding buspirone to medications. Symptoms improved after approx 2 weeks. However, became shaky/tremors with exertion. 2nd dose 5/3/21- Woken in middle of the night with racing/pounding heart, pain and burning in feet/legs. No treatment sought. Continued to have tremors/jittery feeling with exertion. July- muscle twitching began in legs. August- jittery feeling increased, insomnia and night dizziness began. Woke mid august with racing/pounding heart. Heart rate 50 when lying and 130-150 when upright. Also had increased urination, 5 lb weight loss, diarrhea, flushing/redness after eating and near syncope. Referred to a cardiologist, then referred to autonomic neurologist for tilt table testing. November 2021- diagnosed with pots.  December 2021- started on corlanor Referred to allergist for continued flushing/jittery/tremors with eating March 2022- diagnosed with Mast Cell Activation Syndrome. Treatment- singulair, xyzal, famotidine
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling jittery, Flushing, Insomnia, Mast cell activation syndrome, Muscle twitching
Clinical narrative: First vaccine- immediate pain down left arm. Within 30 minutes- blurred vision, tingling in lips, hands and feet. Treatment- pharmacist instructed drink pedialyte and rest at home 7 days after first vaccine- dry mouth, tremors, racing heart. Went to ER twice.  Family Dr tried adding buspirone to medications. Symptoms improved after approx 2 weeks. However, became shaky/tremors with exertion. 2nd dose 5/3/21- Woken in middle of the night with racing/pounding heart, pain and burning in feet/legs. No treatment sought. Continued to have tremors/jittery feeling with exertion. July- muscle twitching began in legs. August- jittery feeling increased, insomnia and night dizziness began. Woke mid august with racing/pounding heart. Heart rate 50 when lying and 130-150 when upright. Also had increased urination, 5 lb weight loss, diarrhea, flushing/redness after eating and near syncope. Referred to a cardiologist, then referred to autonomic neurologist for tilt table testing. November 2021- diagnosed with pots.  December 2021- started on corlanor Referred to allergist for continued flushing/jittery/tremors with eating March 2022- diagnosed with Mast Cell Activation Syndrome. Treatment- singulair, xyzal, famotidine
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Palpitations, Pollakiuria, Postural orthostatic tachycardia syndrome, Presyncope, Tilt table test positive
Clinical narrative: First vaccine- immediate pain down left arm. Within 30 minutes- blurred vision, tingling in lips, hands and feet. Treatment- pharmacist instructed drink pedialyte and rest at home 7 days after first vaccine- dry mouth, tremors, racing heart. Went to ER twice.  Family Dr tried adding buspirone to medications. Symptoms improved after approx 2 weeks. However, became shaky/tremors with exertion. 2nd dose 5/3/21- Woken in middle of the night with racing/pounding heart, pain and burning in feet/legs. No treatment sought. Continued to have tremors/jittery feeling with exertion. July- muscle twitching began in legs. August- jittery feeling increased, insomnia and night dizziness began. Woke mid august with racing/pounding heart. Heart rate 50 when lying and 130-150 when upright. Also had increased urination, 5 lb weight loss, diarrhea, flushing/redness after eating and near syncope. Referred to a cardiologist, then referred to autonomic neurologist for tilt table testing. November 2021- diagnosed with pots.  December 2021- started on corlanor Referred to allergist for continued flushing/jittery/tremors with eating March 2022- diagnosed with Mast Cell Activation Syndrome. Treatment- singulair, xyzal, famotidine
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Tremor, Tryptase, Weight decreased
Clinical narrative: First vaccine- immediate pain down left arm. Within 30 minutes- blurred vision, tingling in lips, hands and feet. Treatment- pharmacist instructed drink pedialyte and rest at home 7 days after first vaccine- dry mouth, tremors, racing heart. Went to ER twice.  Family Dr tried adding buspirone to medications. Symptoms improved after approx 2 weeks. However, became shaky/tremors with exertion. 2nd dose 5/3/21- Woken in middle of the night with racing/pounding heart, pain and burning in feet/legs. No treatment sought. Continued to have tremors/jittery feeling with exertion. July- muscle twitching began in legs. August- jittery feeling increased, insomnia and night dizziness began. Woke mid august with racing/pounding heart. Heart rate 50 when lying and 130-150 when upright. Also had increased urination, 5 lb weight loss, diarrhea, flushing/redness after eating and near syncope. Referred to a cardiologist, then referred to autonomic neurologist for tilt table testing. November 2021- diagnosed with pots.  December 2021- started on corlanor Referred to allergist for continued flushing/jittery/tremors with eating March 2022- diagnosed with Mast Cell Activation Syndrome. Treatment- singulair, xyzal, famotidine
Age: 76.0
Sex: F
Vaccine: TDAP
Symptoms: Electrocardiogram normal, Feeling abnormal, Feeling cold, Heart rate decreased, Tremor
Clinical narrative: After injection, roughly 10 minutes in, patient began to feel "foggy" in the head. Roughly 10 minutes later she then proceeded to feel cold, with shaking. The shaking lasted roughly 10 minutes then resolved. She had a decrease in heart rate that lasted foughly 5-7 minutes. ECG normal. Vitals then stayed WNL. After initial assessment, EMS was called and was transported via EMS at about 10:20 AM. She never lost consciousness and stood up and walked to the stretcher.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy, Blood test, Pruritus, Rash
Clinical narrative: Itching and multiple rashes of different types lasting over 2 months and still continuing
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram thorax, Dyspnoea, Dyspnoea exertional, Echocardiogram, Electrocardiogram
Clinical narrative: Shortness of Breath / difficulty breathing, primarily when active.   Fatigue.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Full blood count, Positron emission tomogram, Pulmonary function test
Clinical narrative: Shortness of Breath / difficulty breathing, primarily when active.   Fatigue.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Gait disturbance, Headache, Injection site pain
Clinical narrative: Soreness, warmth, and itchy skin at the injection site began on the evening of 5/19/22 (date of vaccination).  On 5/20/22, around mid-day (12:00-1:30pm) more severe adverse reactions occurred.  A headache progressed to migraine progressed and Sumatriptan was taken to alleviate the pain.  Joint pain throughout the body (all major extremities) which caused difficulty walking/ambulating.  Also severe, frequent, consistent muscle spasms and cramps (an inability to lay still for more than 30 seconds), fever, chills, and mild nausea.  The migraine subsided within 90 minutes of taking medicine.  The other symptoms lasted for approximately 2-3 hours.  Note, the spasm were predominately on the left side of the body.  The fever comes and goes, lasting  up to 45 minutes.  Ice packs on my body and a fan were used to quickly cool me down.  As of today 5/22/22, fever continues to come in less frequent waves and seems to be managed with Tylenol, the injection site is still warm to the touch, itchy, and sore.   *I refused to go to the hospital despite the concerns of my husband.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pruritus, Injection site warmth, Migraine, Muscle spasms, Nausea
Clinical narrative: Soreness, warmth, and itchy skin at the injection site began on the evening of 5/19/22 (date of vaccination).  On 5/20/22, around mid-day (12:00-1:30pm) more severe adverse reactions occurred.  A headache progressed to migraine progressed and Sumatriptan was taken to alleviate the pain.  Joint pain throughout the body (all major extremities) which caused difficulty walking/ambulating.  Also severe, frequent, consistent muscle spasms and cramps (an inability to lay still for more than 30 seconds), fever, chills, and mild nausea.  The migraine subsided within 90 minutes of taking medicine.  The other symptoms lasted for approximately 2-3 hours.  Note, the spasm were predominately on the left side of the body.  The fever comes and goes, lasting  up to 45 minutes.  Ice packs on my body and a fan were used to quickly cool me down.  As of today 5/22/22, fever continues to come in less frequent waves and seems to be managed with Tylenol, the injection site is still warm to the touch, itchy, and sore.   *I refused to go to the hospital despite the concerns of my husband.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Soreness, warmth, and itchy skin at the injection site began on the evening of 5/19/22 (date of vaccination).  On 5/20/22, around mid-day (12:00-1:30pm) more severe adverse reactions occurred.  A headache progressed to migraine progressed and Sumatriptan was taken to alleviate the pain.  Joint pain throughout the body (all major extremities) which caused difficulty walking/ambulating.  Also severe, frequent, consistent muscle spasms and cramps (an inability to lay still for more than 30 seconds), fever, chills, and mild nausea.  The migraine subsided within 90 minutes of taking medicine.  The other symptoms lasted for approximately 2-3 hours.  Note, the spasm were predominately on the left side of the body.  The fever comes and goes, lasting  up to 45 minutes.  Ice packs on my body and a fan were used to quickly cool me down.  As of today 5/22/22, fever continues to come in less frequent waves and seems to be managed with Tylenol, the injection site is still warm to the touch, itchy, and sore.   *I refused to go to the hospital despite the concerns of my husband.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Breast discharge, Breast mass, Erythema, Mammogram normal, Nipple disorder
Clinical narrative: Infection of the left breast nipple which by sight showed breakage of skin on the right side and flesh protruding.  The area was very red with a discharge.  Mammogram was perform which was normal. Also a sonogram was performed and showed a large mass at the breast nipple and abnormal area under the arm pit.  Also saw a breast surgeon as a follow up.  The breast surgeon came to no conclusion as to the cause, but thought maybe a polyp  in the nipple.  The nipple was very painful and eventually healed but the nipple is now flat and dis-formed.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Nipple infection, Nipple pain, Polyp, Skin disorder, Ultrasound breast abnormal
Clinical narrative: Infection of the left breast nipple which by sight showed breakage of skin on the right side and flesh protruding.  The area was very red with a discharge.  Mammogram was perform which was normal. Also a sonogram was performed and showed a large mass at the breast nipple and abnormal area under the arm pit.  Also saw a breast surgeon as a follow up.  The breast surgeon came to no conclusion as to the cause, but thought maybe a polyp  in the nipple.  The nipple was very painful and eventually healed but the nipple is now flat and dis-formed.
Age: 9.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema multiforme, Pain in extremity, Pyrexia, Swelling face, Urticaria
Clinical narrative: Sore arm within hours. Slight fever of the course of the next day. On morning of 22 May, woke up with high fever, swelling in face and what appeared to be hives all over body. Taken to ER immediately and attending doctor diagnosed with Erythema Multiforme minor.
Age: 66.0
Sex: M
Vaccine: PNC20
Symptoms: Injection site pain, Pyrexia
Clinical narrative: extreme soreness at inj site and low grade fever
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site induration, Injection site warmth, Loss of consciousness, Muscular weakness
Clinical narrative: The next morning (5/18/22), she stated she had weakness in the legs.  EMS came, said vitals were fine and no need to transport.  That afternoon, she was coming to dining room for dinner when I was at facility.  On 5/21/22, she passed out while being changed.  She had not been wearing her oxygen. (She is supposed to wear it all the time but is not compliant per the staff.) EMS was called.  It was noted that her injection site was warm to touch and solid at the site.  EMS transported her to the hospital.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 94.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal neoplasm, Blood uric acid increased, Burkitt's lymphoma, Computerised tomogram abdomen abnormal, Death
Clinical narrative: This report is from a hospital on March 29th an approximate one month history of decreased appetite and malaise and a new onset shortness of breath.  Pulmonary embolism was suspected.  11 cm abdominal tumor was found.  Pt was transferred to another hospital for care.  A week later the tumor was 27 cm and 8 days after that the pt had reportedly died.   The patient had been diagnosed with GIST vs Burkitt's lymphoma with mets to liver and peritoneum & PE of RLL
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Decreased appetite, Dyspnoea, Gastrointestinal stromal tumour, Laboratory test abnormal, Malaise
Clinical narrative: This report is from a hospital on March 29th an approximate one month history of decreased appetite and malaise and a new onset shortness of breath.  Pulmonary embolism was suspected.  11 cm abdominal tumor was found.  Pt was transferred to another hospital for care.  A week later the tumor was 27 cm and 8 days after that the pt had reportedly died.   The patient had been diagnosed with GIST vs Burkitt's lymphoma with mets to liver and peritoneum & PE of RLL
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Metastases to liver, Metastases to peritoneum, Pulmonary embolism
Clinical narrative: This report is from a hospital on March 29th an approximate one month history of decreased appetite and malaise and a new onset shortness of breath.  Pulmonary embolism was suspected.  11 cm abdominal tumor was found.  Pt was transferred to another hospital for care.  A week later the tumor was 27 cm and 8 days after that the pt had reportedly died.   The patient had been diagnosed with GIST vs Burkitt's lymphoma with mets to liver and peritoneum & PE of RLL
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 92.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 53.0
Sex: F
Vaccine: COVID19, DTAP, FLU4
Symptoms: Pemphigus
Clinical narrative: Pemphigus vulgaris
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Dizziness, Fatigue, Headache, Lymphadenopathy
Clinical narrative: That night: pain in arm/head ache.  Next day: head ache/worsening of pain in arm/ swelling in supraclavicular lymph node/ sweeping about egg size in armpit (all swelling on same side as shot), nausea/ fatigue/ vomiting/ feeling of almost passing out/diarrhea
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pain in extremity, Vomiting
Clinical narrative: That night: pain in arm/head ache.  Next day: head ache/worsening of pain in arm/ swelling in supraclavicular lymph node/ sweeping about egg size in armpit (all swelling on same side as shot), nausea/ fatigue/ vomiting/ feeling of almost passing out/diarrhea
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 90.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Angina pectoris, Back injury, Coronary arterial stent insertion, Coronary artery disease, Electrocardiogram abnormal
Clinical narrative: Sudden painful, almost paralyzing,  Heart Attack - Coronary Artery Disease, Drug eluding Stent in Left Anterior ( Widow-Maker ) descending artery Sudden Onset when on my second or third lap swimming in the daily Swimming program the morning of Wed, Oct 13, 2021. Was on a course of Prednisone for a Back injury suffered the week before. I thought I was having a bad case of Angina/Chest Pain since I had a similar (NOT Heart Attack ) documented event in 2013. I managed to get myself home and take the prescribed Prednisone hoping that would give me relief...but it did NOT.  Had son take me to ER who then transferred me the the Medical Center.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Myocardial infarction
Clinical narrative: Sudden painful, almost paralyzing,  Heart Attack - Coronary Artery Disease, Drug eluding Stent in Left Anterior ( Widow-Maker ) descending artery Sudden Onset when on my second or third lap swimming in the daily Swimming program the morning of Wed, Oct 13, 2021. Was on a course of Prednisone for a Back injury suffered the week before. I thought I was having a bad case of Angina/Chest Pain since I had a similar (NOT Heart Attack ) documented event in 2013. I managed to get myself home and take the prescribed Prednisone hoping that would give me relief...but it did NOT.  Had son take me to ER who then transferred me the the Medical Center.
Age: 89.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Arrhythmia, Electrocardiogram ambulatory abnormal, Exercise tolerance decreased, Sinus bradycardia, Sinus tachycardia
Clinical narrative: I experienced heart arrhythmia starting 2 days after my second dose.  It lasted for 4 months, approximately.  I couldn?t run or exercise anymore, and called the ambulance once because I thought I was having a heart attack.  No treatment, and eventually it resolved itself.  I didn?t get seen by a doctor immediately because my health insurance.  When I got new insurance, I went to the doctor, but by that time I was pretty much back to normal and exercising again.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Supraventricular extrasystoles
Clinical narrative: I experienced heart arrhythmia starting 2 days after my second dose.  It lasted for 4 months, approximately.  I couldn?t run or exercise anymore, and called the ambulance once because I thought I was having a heart attack.  No treatment, and eventually it resolved itself.  I didn?t get seen by a doctor immediately because my health insurance.  When I got new insurance, I went to the doctor, but by that time I was pretty much back to normal and exercising again.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Anxiety, Arthralgia, Electric shock sensation, Fatigue
Clinical narrative: The following morning I was fatigued but also started receiving an acute pain in my left hip that I have never experienced before taking the Covid shot. My experience of the pain felt like an electrical shot wave, short pain but sharp that was on going sporadically. The pain started to lessen before going to bed around 11:00 pm. By morning it had almost disappeared and the following days ahead I only felt it a few times until Sunday morning May 22, it started to resurface.  I had hope it was the end of this new occurrence.        I know how important it is to get vaccine, but with this strange occurrence and pain, I am now apprehensive about my next shot if this doesn't go away.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Lip swelling, Swelling face
Clinical narrative: 30 hours later swelling of lip and cheek
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pain, Pain, Pain in extremity
Clinical narrative: My arm hurts now for two years where injection was given
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 44.0
Sex: M
Vaccine: COVID19, UNK, UNK
Symptoms: Catheterisation cardiac, Electrocardiogram, Myocardial infarction
Clinical narrative: Vaccine given COVID Booster at Hospital, no access to lot number or other more specific info for vaccine. A little over a week later the pt had a myocardial infarction and was admitted to Hospital.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: Pfizer 2 dose series is indicated to be spaced out at 21 days per MFG instructions. Patient verbally reported receiving Pfizer dose #1 on 04/22/2022. Second dose of Pfizer was administered on 05/11/2022. However when patient presented vaccine card to be updated with second dose date, date recorded on vaccine card for dose #1 was 4/28/2022.  This was a spacing of 13 days, patient was placed in observation for 15mins per company protocol, and no sign and symptoms of adverse reaction was noted. Patient was advised of administration error, and to RTC for follow up dose of Pfizer  in 3 weeks (06/01/2022) per CDC administration error recommendation updated as of 02/22/2022. Patient verbalized instructions, reminder card given.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Unevaluable event
Clinical narrative: patient hospitalized
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 30.0
Sex: U
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by agency for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F. However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 13.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 41.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Contracted shingles.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Acute kidney injury, COVID-19, Chest pain, Chronic kidney disease, Condition aggravated
Clinical narrative: COVId Vaccine Breakthrough CAse  Pfizer Dose 1 3/11/21 (EN6205) Pfizer Dose 2 4/1/21 (EP7533) COVID Positive 12/3/21  12/3/21: History is obtained from patient as well as by personal review of records.  Patient is 75-year-old gentleman with known history of coronary artery disease, congestive heart failure, AICD, COPD, chronic kidney disease and other medical problems. Presented to emergency department with generalized muscle pain, neck pain, left lower chest pain radiating to flank, and feeling of being unwell for 1 week following a gathering.  Denied subjective fevers.  Denied shortness of air or hemoptysis.  Denied firing of pacemaker.  Denied recent weight gain or weight loss. Denied orthopnea or paroxysmal nocturnal dyspnea.  EKG showed paced rhythm.  He tested positive for  SARS-CoV-2.  12/7/21: Patient is a 75 year old male with a history of CKD, CAD, CHF, and AFib on AC.  He was admitted on 12/4/2021 with left lower lobe community-acquired pneumonia, COVID positivity, AKI on CKD, hypokalemia, hypomagnesemia, and elevated cardiac enzymes.  Cardiology was consulted.  And they ruled out ACS.  They did make some cardiac med changes to control bursts of tachycardia.  His electrolytes were repleted.  He was started on courses of Azithromycin, Rocephin, and remdesivir.  He has not required any supplemental oxygen.  His vitals have been grossly stable over the last 48 hours his kidney injury has resolved.  He is back to his baseline renal function.  He has not had a fever or cough.  Reports that he feels great today.  Wants to go home.  We discussed the benefits of staying to complete his 5th dose of remdesivir, and the patient opted to go home today after his 4th.  He denies shortness of breath at rest, dyspnea on exertion, chest pain, palpitations.  He was evaluated by Physical therapy, and they felt the patient would benefit from visiting nurse services. The patient was agreeable. Patient is being discharged home with visiting nurse services for nursing and physical therapy.  He also enrolled in a safe at home program.  Those nurses will follow-up with him at discharge.  He should discontinue Coreg.  He should continue Toprol XL 100 mg p.o. b.i.d. and Azithromycin 250 g p.o. daily x4 days.  He should continue to self-quarantine x7 days.  He should follow-up with his primary care provider in 1-2 weeks.  He should follow-up with his primary cardiologist in 2 weeks. He has been provided patient education for community-acquired pneumonia, acute kidney injury, hypokalemia, COVID, Azithromycin, and Toprol XL.  I have answered all of his questions and addressed all of his concerns.  The patient is being discharged in improved and stable condition.